Genprex (NASDAQ:GNPX – Get Free Report) posted its earnings results on Monday. The company reported ($1.15) EPS for the quarter, beating analysts’ consensus estimates of ($13.00) by $11.85, reports.
Genprex Stock Performance
Shares of GNPX stock opened at $1.77 on Tuesday. Genprex has a fifty-two week low of $1.71 and a fifty-two week high of $55.00. The firm has a market capitalization of $5.52 million, a price-to-earnings ratio of -0.07 and a beta of -0.77. The stock’s 50-day simple moving average is $2.13 and its 200-day simple moving average is $4.90.
Analyst Ratings Changes
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genprex in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.
Institutional Trading of Genprex
An institutional investor recently raised its position in Genprex stock. Susquehanna International Group LLP boosted its stake in shares of Genprex (NASDAQ:GNPX – Free Report) by 11.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 340,056 shares of the company’s stock after purchasing an additional 35,661 shares during the period. Susquehanna International Group LLP owned approximately 27.20% of Genprex worth $58,000 at the end of the most recent reporting period. 14.05% of the stock is owned by institutional investors.
About Genprex
Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.
In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.
Recommended Stories
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.
